Abstract
Several authors, such as Dale and Laidlaw (1912), Fromherz (1926), Glaubach and Molitor (1932), Lipschitz and Klar (1933), and Simon (1933), used the isolated uterus of virgin guinea pigs as a sensitive test for determination of oxytocin activity. The isolated uterus of the rat (Holton 1948) is less sensitive, but, in contrast to the guinea pig, the rat uterus shows no spontaneous contractions in solutions with low calcium and glucose concentrations. Historically, the method has been adopted by several pharmacopoeias, e.g., by the British Pharmacopoeia (1988). The United States Pharmacopeia 23 (1995) uses the isolated guinea pig uterus for determination of oxytocin activity in vasopressin preparations. Physicochemical assays are now used for standardizing drug content, instead of the biological responses.
References and Further Reading
Isolated Uterus
Berde B, Doepfner W, Konzett H (1957) Some pharmacological actions or four synthetic analogues of oxytocin. Br J Pharmacol 12:209–214
Berde B, Cerletti A, Konzett H (1959) The biological activity of a series of peptides related to oxytocin. In: Caldeyro-Barcia R, Heller H (eds) Oxytocin: intern sympos montevideo. Pergamon, London
Boissonnas RA (1960) The chemistry of oxytocin and vasopressin. In: Schachter M (ed) Polypeptides which affect smooth muscles and blood vessels. Pergamon, London, pp 7–19
Boissonnas RA, Guttmann S, Berde B, Konzett H (1961) Relationships between the chemical structures and the biological properties of the posterior pituitary hormones and their synthetic analogues. Experientia 1:377–390
British Pharmacopoeia, vol II (1988) Biological assay of oxytocin. Appendix XIV C: A171. HMSO, London
Burn HJ, Finney DJ, Goodwin LG (1952) Biological standardization, 2nd edn, 2nd impression. Oxford University Press, Oxford
Dale H, Laidlaw J (1912) A method for standardising pituitary (infundibular) extracts. J Pharmacol Exp Ther 4:73–95
Fromherz K (1926) Bemerkungen zur Auswertung von Hypophysenextrakt am Meerschweinchenuterus. Naunyn-Schmiedebergs Arch Exp Pathol Pharmakol 113:113–123
Glaubach S, Molitor H (1932) Vergleich der Auswertungsmethoden von Gesamtextrakten des Hypophysenhinterlappens am isolierten Meerrschweinchenuterus und an der Diuresehemmung von Hunden, Ratten und Mäusen. Naunyn-Schmiedebergs Arch Exp Pathol Pharmakol 166:243–264
Guissani DA, Jenkins SL, Mecenas CA, Owiny JR, Wentwort RA, Winter JA, Derks JB, Honnebier MBOM, Nathanielz PW (1995) The oxytocin (OT) antagonist Atosiban (ATO) prolongs gestation in the rhesus monkey. J Soc Gynecol Investig 2:265
Holton P (1948) A modification of the method of Dale and Laidlaw for the standardization of posterior pituitary extract. Br J Pharmacol 3:328–334
Kruse J (1986) Oxytocin: pharmacology and clinical application. J Fam Pract 23:473–479
Liebmann C, Nawrath S, Ludwig B, Paegelow I (1993) Pharmacological and molecular actions of the bradykinin B2 receptor antagonist, Hoe 140 in the rat uterus. Eur J Pharmacol 235:183–188
Lipschitz W, Klar F (1933) Die Abhängigkeit der Wirkung uteruserregender Mittel (Histamin und Ergotamin) von Konzentration und Reaktionstemperatur. Naunyn-Schmiedebergs Arch Exp Path Pharmakol 174:223–244
Munsick RA, Sawyer WH, van Dyke HB (1960) Avian neurohyophyseal hormones: pharmacological properties and tentative identification. Endocrinology 66:860–871
Murray WJ, Miller JW (1960) Oxytocin-induced “cramping” in the rat. J Pharmacol Exp Ther 128:372–379
Pettibone DJ, Guidotti MT, Harrell CM, Jasper JR, Lis EV, O’Brien JA, Reiss DR, Woyden CJ, Bock MG, Evans BE, Freidinger RM, Williams DP, Murphy MG (1996) Progress in the development of oxytocin antagonists for use in preterm labor. Adv Exp Biol Med 395:601–612
Schaumann W (1937) Wirkstoffe des Hinterlappens der Hypophyse. In: Handbuch exper Pharmakol, vol 3. Springer, Berlin/Heidelberg/New York, pp 61–150
Schübel K, Gehlen W (1933) Eine neue, zuverlässige Methode zur Standardisierung von Hypophysen-Hinterlappenextrakten. Naunyn-Schmiedebergs Arch Exp Pathol Pharmakol 173:633–641
Simon A (1933) The secretion of the posterior lobe of the hypophysis after the administration of drugs. J Pharmacol 49:375–386
Thorp RH (1962) Posterior pituitary hormones. In: Dorfman RI (ed) Methods in hormone research, vol II. Academic, New York, pp 495–516
Thorp RH (1969) Posterior pituitary hormones. In: Dorfman RI (ed) Methods in hormone research, vol IIA. Academic, New York, pp 457–480
United States Pharmacopeia 23 (1995) Vasopressin injection. The United States Pharmacopeia 23. United States Pharmacopoeial Convention, Rockville, pp 1622–1623
Van Dyke HB, Adamsons K, Engel SL (1955) I. Pituitary hormones. Aspects of the biochemistry and physiology of the neurohyophyseal hormones. Recent Prog Horm Res 11:1–41
Vogel G, Hergott J (1963) Pharmakologische Untersuchungen über O-Methyl-tyrosin2-lysin8-Vasopressin. Arzneimittelforschung 13:415–421
Chicken Blood Pressure
British Pharmacopoeia, vol II (1988) Biological assay of oxytocin. Appendix XIV C:A171. HMSO, London
Coon JM (1939) A new method for the assay of posterior pituitary extracts. Arch Int Pharmacodyn Ther 62:79–99
DuVigneaud V, Fitt PS, Bodanszky M, O’Connell M (1960) Synthesis and some pharmacological properties of a peptide derivative of oxytocin: glycyloxytocin. Proc Soc Exp Biol Med 104:653–656
Munsick RA, Sawyer WH, van Dyke HB (1960) Avian neurohyophyseal hormones: pharmacological properties and tentative identification. Endocrinology 66:860–871
Thorp RH (1962) Posterior pituitary hormones. In: Dorfman RI (ed) Methods in hormone research, vol II. Academic, New York, pp 495–516
Thorp RH (1969) Posterior pituitary hormones. In: Dorfman RI (ed) Methods in hormone research, vol IIA. Academic, New York, pp 457–480
United States Pharmacopeia 23 (1995a) Design and analysis of biological assays. The United States Pharmacopeial Convention, Rockville, pp 1705–1715
United States Pharmacopeia 23 (1995b) Oxytocin injection. The United States Pharmacopeial Convention, Rockville, pp 1148–1149
Van Dyke HB, Adamsons K, Engel SL (1955) I. Pituitary hormones. Aspects of the biochemistry and physiology of the neurohyophyseal hormones. Recent Prog Horm Res 11:1–41
Milk Ejection in the Lactating Rabbit or Rat
Berde B, Cerletti A (1957) Démonstration expérimentale de l’action de l’ocytocine sur la glande mammaire. Gynaecologia 144:275–278
British Pharmacopoeia, vol II (1988) Biological assay of oxytocin. Appendix XIV C:A171. HMSO, London
Munsick RA, Sawyer WH, van Dyke HB (1960) Avian neurohyophyseal hormones: pharmacological properties and tentative identification. Endocrinology 66:860–871
Thorp RH (1962) Posterior pituitary hormones. In: Dorfman RI (ed) Methods in hormone research, vol II. Academic, New York, pp 495–516
Thorp RH (1969) Posterior pituitary hormones. In: Dorfman RI (ed) Methods in hormone research, vol IIA. Academic, New York, pp 457–480
Tindal JS, Yokoyama A (1962) Assay of oxytocin by the milk-ejection response in the anesthetized lactating guinea pig. Endocrinology 71:196–202
van Dyke HB (1959) Some features of the pharmacology of oxytocin. In: Caldeyro-Barcia R, Heller H (eds) Oxytocin: Intern Sympos Montevideo. Pergamon, London, pp 48–67
Van Dyke HB, Adamsons K, Engel SL (1955) I. Pituitary hormones. Aspects of the biochemistry and physiology of the neurohyophyseal hormones. Recent Prog Horm Res 11:1–41
Oxytocin Receptor Determination
Chan WY, Wo NC, Cheng LL, Manning M (1996) Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor. J Pharmacol Exp Ther 277:999–1003
Elands J, Barberis C, Jard S, Tribollet E, Dreifuss JJ, Bankowski K, Manning M, Sawyer WH (1987) 125I-labelled d(CH2)5[Tyr(Me)2, Thr4, Tyr-NH29]OTV. A selective oxytocin receptor ligand. Eur J Pharmacol 147:197–207
Evans BE, Lundell GF, Gilbert KF, Bock MG, Rittle KE, Carroll LA, Williams PD, Pawluczyk JM, Leighton JL, Young MB, Erb JM, Hobbs DW, Gould NP, DiPardo RM, Hoffman JB, Perlow DS, Whitter WL, Veber DF, Pettibone DJ, Clineschmidt BV, Anderson PS, Freidinger RM (1993) Nanomolar-affinity, non-peptide oxytocin receptor antagonists. J Med Chem 36:3993–4005
Freidinger RM, Pettibone DJ (1997) Small molecule ligands for oxytocin and vasopressin receptors. Med Res Rev 17:1–7
Jeng YJ, Lolait SJ, Strakova Z, Chen C, Copland JA, Mellman D, Hellmich MR, Soloff MS (1996) Molecular cloning and functional characterization of the oxytocin receptor from a rat pancreatic cell line (RINm5F). Neuropeptides 30:557–565
Klein U, Jurzak M, Gerstberger R, Fahrenholz F (1995) A new tritiated oxytocin receptor radioligand – synthesis and application for localization of central oxytocin receptors. Peptides 16:851–857
Maggi M, Fantoni G, Baldi E, Cioni A, Rossi S, Vanelli GB, Melin P, Åkerlund M, Serio M (1994) Antagonists for the human oxytocin receptor: an in vitro study. J Reprod Fertil 101:345–352
Manning M, Cheng LL, Klis A, Stoev S, Przybylski J, Bankowski K, Sawyer WH, Barberis C, Chan WY (1995) Advances in the design of selective antagonists, potential tocolytics and radioiodinated ligands for oxytocin receptors. In: Ivell R, Russell J (eds) Oxytocin. Plenum, New York, pp 559–584
McPherson GA (1985a) KINETIC, EBDA, LIGAND, LOWRY: a collection of radioligand binding analysis programs. Elsevier, Amsterdam
McPherson GA (1985b) Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Meth 14:213–228
Pak SC, Bertoncini D, Meyer W, Scaunas D, Flouret G, Wilson R Jr (1994) Comparison of binding affinity of oxytocin antagonists to human and rat oxytocin receptors their correlation to the rat oxytocic bioassay. Biol Reprod 51:1140–1144
Peter J, Burbach H, Adan RA, Lolait SJ, van Leeuwen FW, Mezey E, Palkovits M, Barberis C (1995) Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. Cell Mol Neurobiol 15(5):573–595
Pettibone DJ, Freidinger RM (1997) Discovery and development of non-peptide antagonists of peptide hormone receptors. Biochem Soc Trans 25:1051–1057
Pettibone DJ, Woyden CJ, Totaro JA (1990) Identification of functional oxytocin receptors in lactating rat mammary gland in vitro. Eur J Pharmacol 188:235–242
Pettibone DJ, Clineschmidt BV, Lis EV, Reiss DR, Totaro JA, Woyden CJ, Bock MG, Freidinger RM, Tung RD, Veber DF, Williams DP, Lowensohn RI (1991) In vitro pharmacological profile of a novel structural class of oxytocin antagonists. J Pharmacol Exp Ther 256:304–308
Pettibone DJ, Clineschmidt BV, Guidotti MT, Lis EV, Reiss DR, Woyden CJ, Bock MG, Evans BE, Freidinger RM, Hobbs DW, Veber DF, Williams PD, Chiu SHL, Thompson KL, Schorn TW, Siegl PKS, Kaufman MJ, Cukierski MA, Haluska GJ, Cook MJ, Novy MJ (1993a) L-368,899, a potent orally active oxytocin antagonist for potential use in preterm labor. Drug Dev Res 30:129–142
Pettibone DJ, Clineschmidt BV, Kishel MT, Lis EV, Reiss DR, Woyden CJ, Evans BE, Freidinger RM, Veber DF, Cook MJ, Haluska GJ, Novy MJ, Lowensohn RI (1993b) Identification of an orally active, nonpeptidyl oxytocin antagonist. J Pharmacol Exp Ther 264:308–314
Pettibone DJ, Guidotti MT, Harrell CM, Jasper JR, Lis EV, O’Brien JA, Reiss DR, Woyden CJ, Bock MG, Evans BE, Freidinger RM, Williams DP, Murphy MG (1996) Progress in the development of oxytocin antagonists for use in preterm labor. Adv Exp Biol Med 395:601–612
Salvatore CA, Woyden CJ, Guidotti MT, Pettibone DJ, Jacobson MA (1998) Cloning and expression of the rhesus monkey oxytocin receptor. J Recept Signal Transduct Res 18:15–24
Thibonnier M, Conarty DM, Preston JA, Wilkins PL, Berti-Mattera R (1998) Molecular pharmacology of human vasopressin receptors. Adv Exp Biol 449:251–276
Young LJ, Hout B, Nilsen R, Wang Z, Insel TR (1996) Species differences in central oxytocin receptor expression: comparative analyses of promoter sequences. J Neuroendocrinol 8:777–783
Vasopressin
Grant FD (2000) Genetic models of vasopressin deficiency. Exp Physiol 85:203S–209S
Herman JP, Sladek CD, Hansen CT, Gash DM (1986) Characterization of a new rodent model of diabetes insipidus: the Roman high avoidance rat homozygous for diabetes insipidus. Neuroendocrinology 43(3):340–347
Laycock JF, Chatterji U, Seckl JR, Gartside IB (1994) The abnormal quinine drinking aversion in the Brattleboro rat with diabetes insipidus is reversed by the vasopressin agonist DDAVP: a possible role for vasopressin in the motivation to drink. Physiol Behav 55:407–412
Lloyd DJ, Hall FW, Tarantino LM, Gekakis N (2005) Diabetes insipidus in mice with a mutation in aquaporin-2. PLoS Genet 1(2):e20
McCabe JT, Almasan K, Lehmann E, Hänze J, Lang RE, Pfaff DW, Ganten D (1988) Vasopressin gene expression in hypertensive, normotensive, and diabetes insipidus rats. Clin Exp Hypertens A A10(Suppl 1):131–142
Nyunt-Wai V, Laycock JF (1990) The pressor response to vasopressin is not attenuated by hypertonic NaCl in the anaesthetized Brattleboro rat. J Physiol 430:35P
Petersen MB (2006) The effect of vasopressin and related compounds at V1a and V2 receptors in animal models relevant to human disease. Basic Clin Pharmacol Toxicol 99(2):96–103
Schmale H, Richter D (1984) Single base deletion in the vasopressin gene is the cause of diabetes insipidus in Brattleboro rats. Nature 308:705–709
Schmale H, Ivell R, Breindl M, Darmer D, Richter D (1984) The mutant vasopressin gene from diabetes insipidus (Brattleboro) rats is transcribed but the message is not efficiently translated. EMBO J 3:3289–3293
Sokol HW, Valtin H (eds) (1982) The Brattleboro rat. Ann N Y Acad Sci 394
Szot P, Dorsa DM (1992) Cytoplasmic and nuclear vasopressin RNA in hypothalamic and extrahypothalamic neurons of the Brattleboro rat: an in situ hybridization study. Mol Cell Neurosci 3:224–236
Valtin H, Sawyer WH, Sokol HW (1965) Neurohypophyseal principles in rats homozygous and heterozygous for hypothalamic diabetes insipidus (Brattleboro strain). Endocrinology 77:701–706
Vasopressor Activity
Altura BM, Altura BT (1984) Actions of vasopressin, oxytocin, and synthetic analogs on vascular smooth muscle. Fed Proc 43:80–86
British Pharmacopoeia, vol II (1988) Biological assay of argipressin. Appendix XIV C:A172–A173. HMSO, London
Dekansky J (1952) The quantitative assay of vasopressin. Br J Pharmacol 7:567–572
DuVigneaud V, Fitt PS, Bodanszky M, O’Connell M (1960) Synthesis and some pharmacological properties of a peptide derivative of oxytocin: glycyloxytocin. Proc Soc Exp Biol Med 104:653–656
Hamilton HC (1912) The pharmacological assay of pituitary preparations. J Am Pharm Assoc Am Pharm Assoc 1:1117–1119
Knape JTA, van Zwieten PA (1988) Vasoconstrictor activity of vasopressin in the pithed rat. Arch Int Pharmacodyn Ther 291:142–152
Sawyer WH (1961) Neurohypophyseal hormones. Pharmacol Rev 13:225–277
Thorp RH (1969) Posterior pituitary hormones. In: Dorfman RI (ed) Methods in hormone research, vol IIA. Academic, New York, pp 457–480
USP 23 (1995a) Design and analysis of biological assays. The United States Pharmacopeial Convention, Rockville, pp 1705–1715
USP 23 (1995b) Vasopressin injection. The United States Pharmacopeial Convention, Rockville, pp 1622–1623
Van Dyke HB, Adamsons K, Engel SL (1955) I. Pituitary hormones. Aspects of the biochemistry and physiology of the neurohyophyseal hormones. Recent Prog Horm Res 11:1–41
Vogel G, Hergott J (1963) Pharmakologische Untersuchungen über O-Methyl-tyrosin2-lysin8-Vasopressin. Arzneimittelforschung 13:415–421
Antidiuretic Activity in the Conscious Rat
British Pharmacopoeia, vol II (1988) Biological assay of desmopressin. Appendix XIV D:A173. HMSO, London
Burn JH (1931) Estimation of the antidiuretic potency of pituitary (posterior lobe) extract. Q J Pharm 4:517–529
Schaumann W (1937) Wirkstoffe des Hinterlappens der Hypophyse. In: Handbuch exper Pharmakol, vol 3. Springer, Berlin/Heidelberg/New York, pp 61–150
Thorp RH (1962) Posterior pituitary hormones. In: Dorfman RI (ed) Methods in hormone research, vol II. Academic, New York, pp 495–516
Thorp RH (1969) Posterior pituitary hormones. In: Dorfman RI (ed) Methods in hormone research, vol IIA. Academic, New York, pp 457–480
Van Dyke HB, Adamsons K, Engel SL (1955) I. Pituitary hormones. Aspects of the biochemistry and physiology of the neurohyophyseal hormones. Recent Prog Horm Res 11:1–41
Vogel G, Hergott J (1963) Pharmakologische Untersuchungen über O-Methyl-tyrosin2-lysin8-Vasopressin. Arzneimittelforschung 13:415–421
Antidiuretic Activity in the Rat in Ethanol Anesthesia
Berde B, Cerletti A (1961) Über die antidiuretische Wirkung von synthetischem Lysin-Vasopressin. Helv Physiol Acta 19:135–150
Dettelbach HR (1958) A method for assaying small amounts of antidiuretic substances with notes on some properties of vasopressin. Am J Physiol 192:379–386
Dicker SE (1953) A method for the assay of very small amounts of antidiuretic activity with a note on the antidiuretic titer of rats’ blood. J Physiol (Lond) 122:149–157
Munsick RA, Sawyer WH, van Dyke HB (1960) Avian neurohyophyseal hormones: pharmacological properties and tentative identification. Endocrinology 66:860–871
van Dyke HB, Ames RG (1951) Alcohol diuresis. Acta Endocrinol 7:110–121
Spasmogenic Activity of Vasopressin
Schaumann W (1937) Wirkstoffe des Hinterlappens der Hypophyse. In: Handbuch exper Pharmakol, vol 3. Springer, Berlin/Heidelberg/New York, pp 61–150
Simon A (1933) The secretion of the posterior lobe of the hypophysis after the administration of drugs. J Pharmacol 49:375–386
Vogel G, Hergott J (1963) Pharmakologische Untersuchungen über O-Methyl-tyrosin2-lysin8-Vasopressin. Arzneimittelforschung 13:415–421
Vasopressin Receptor Determination
Ala Y, Morin D, Mahé E, Cotte N, Mouillac B, Jard S, Barberis C, Tribollet E, Dreifuss JJ, Sawyer WH, Wo NC, Chan WY, Kolodziejczyk AS, Chen LL, Manning M (1997) Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors. Eur J Pharmacol 331:285–293
Albright JD, Chan PS (1997) Recent advances in the discovery of vasopressin antagonists: peptide and nonpeptide V1a and V2 receptor antagonists. Curr Pharm Des 3:615–632
Barberis C, Ballestre MN, Jard S, Tribollet E, Arsenijevic Y, Dreifuss JJ, Bankowski K, Manning M, Chan WY, Schlosser SS, Holsboer F, Elands J (1995) Characterization of a novel linear radioiodinated vasopressin antagonist: an excellent radioligand for vasopressin V1a receptors. Neuroendocrinology 62:135–146
Carnazzi E, Aumelas A, Phalipou S, Mouillac B, Guillon G, Barberis C, Seyer R (1997) Efficient photoaffinity labeling of the rat V1a vasopressin receptor using a linear azidopeptidic antagonist. Eur J Biochem 247:906–913
Elands J, Barberis C, Jard S, Lammek B, Manning M, Sawyer WH, de Kloet ER (1988) 125I-d(CH2)5[Tyr(Me)2, Tyr(NH2)9]AVP: iodination and binding characteristics of a vasopressin receptor ligand. FEBS Lett 229:251–255
Gaillard RC, Schoeneberg P, Favrod-Coune CA, Muller AF, Marie J, Bockaert J, Jard S (1984) Properties of rat anterior pituitary vasopressin receptors: relation to adenylate cyclase and the effect of corticotropin-releasing factor. Proc Natl Acad Sci U S A 81:2907–2911
Gal S-L, Raufaste D, Marty E, Garcia C, Maffrand JP, Le Fur G (1994a) Binding of [3H]SR49059, a potent non-peptide vasopressin antagonist, to rat and human liver membranes. Biochem Biophys Res Commun 199:353–369
Gal S-L, Bourrié B, Raufaste D, Carayon P, Garcia C, Maffrand JP, Le Fur G, Casellas P (1994b) Effect of a new, potent, non-peptide vasopressin V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3 T3 cells. Biochem Pharmacol 47:633–641
Gopalakrishnan V, Triggle CR, Sulakhe PV, McNeill JR (1986) Characterization of a specific, high affinity [3H]arginine8 vasopressin-binding site in liver microsomes from different strains of rats and the role of magnesium. Endocrinology 118:990–997
Howl J, Wheatley M (1995) Molecular pharmacology of V1a vasopressin receptors. Gen Pharmacol 26:1143–1152
Kelly JM, Abrahams JM, Phillips PA, Mendelsohn FAO, Grzonka Z, Johnston CI (1989) [125 J]-[d(CH2)5, Sar7]AVP: a selective ligand for V1 vasopressin receptors. J Recept Res 9:27–41
Munson PV, Rodbard D (1980) Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220–239
Nitschke R, Fröbe U, Greger R (1991) Antidiuretic hormone acts via V1 receptors on intracellular calcium in the isolated perfused rabbit cortical thick ascending limb. Pflugers Arch 417:622–632
Ogawa H, Yamashita H, Kondo K, Yamamura Y, Miyamoto H, Kan K, Kitano K, Tanaka M, Nakaya K, Nakamura S, Mori T, Tominaga M, Yabuuchi Y (1996) Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds. J Med Chem 39:3547–3555
Pávó I, Kojro E, Fahrenholz F (1993) Synthesis and binding characteristics of two sulfhydryl-reactive probes for vasopressin receptors. FEBS Lett 316:59–62
Pearlmutter AF, Szkrybalo M, Pettibone G (1985) Specific arginine vasopressin binding in particulate membranes from rat aorta. Peptides 6:427–431
Phalipou S, Cotte N, Carnazzi E, Seyer R, Mahe E, Jard S, Barberis C, Mouillac B (1997) Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem 272:26936–26944
Saito M, Tahara A, Sugimoto T (1997) 1-Desamino-8-d-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Biochem Pharmacol 53:1711–1717
Serradeil-Le Gal C, Wagnon J, Garcia C, Laccour C, Guiraudou P, Christophe B, Villanova G, Nisato D, Maffrand JP, Le Fur G, Guillon G, Cantau B, Barberis C, Trueba M, Ala Y, Jard S (1993) Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest 92:224–231
Tahara A, Tomura Y, Wada KI, Kusayama T, Tsukada J, Takanashi M, Yatsu T, Uchida W, Tanaka A (1997a) Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1a and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 282:301–308
Tahara A, Tomura Y, Wada KI, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A (1997b) Effect of YM087, a potent nonpeptide vasopressin antagonist on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth muscle cells. J Cardiovasc Pharmacol 30:759–766
Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukuda J, Ishii N, Yatsu T, Uchida W, Tanaka A (1998) Pharmacological characterization of the human receptor subtypes stably expressed in Chinese hamster ovary cells. Br J Pharmacol 125:1463–1470
Thibonnier M (1998) Development and therapeutic indications of orally-active vasopressin receptor antagonists. Expert Opin Investig Drugs 7:729–740
Thibonnier M, Auzan C, Madhun Z, Wilkins P, Berti-Mattera L, Clauser E (1994) Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem 269:3304–3310
Thibonnier M, Berti-Mattera LN, Dulin N, Conarty DM, Mattera R (1998) Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. Prog Brain Res 119:147–161
Yatsu T, Tomura Y, Tahara A, Wada K, Tsukada J, Uchida W, Tanaka A, Takenaka T (1997) Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1a and V2 receptor antagonist, in dogs. Eur J Pharmacol 321(2):225–230
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Sandow, J. (2015). Posterior Pituitary Hormones. In: Hock, F. (eds) Drug Discovery and Evaluation: Pharmacological Assays. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27728-3_82-1
Download citation
DOI: https://doi.org/10.1007/978-3-642-27728-3_82-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-27728-3
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences